Related Experiment Video
Updated: Aug 5, 2026
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers
1Department of Obstetrics and Gynecology, Gunma University School of Medicine, Maebashi, Gunma, Japan.
Abstract:
The Smad6 and Smad7 genes are members of the Smad family, involved in the transforming growth factor-beta (TGF-beta) signaling pathway. Mutations in TGF-beta receptors and their cytoplasmic elements of transduction signals commonly accompany various cancers. Using PCR-SSCP analysis we searched for the presence of Smad6 and Smad7 gene mutations in 30 human ovarian cancers and 4 ovarian cancer cell lines, and found that 12 cases (35.3%) had a polymorphism in intron 2 of the Smad6 gene and that 8 cases (23.5%) had a polymorphism at codon 208 in the Smad7 gene. Because these polymorphisms were not accompanied by amino acid substitution, the present results show that the mutations in the Smad6 and Smad7 genes are unlikely to be involved in human ovarian cancers.
Insights
Smad6 and Smad7 gene mutations are uncommon in ovarian cancer. While polymorphisms were found, they did not alter amino acids, suggesting these specific gene mutations are not a primary cause of human ovarian cancers.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- The transforming growth factor-beta (TGF-beta) signaling pathway is crucial in cellular processes.
- Dysregulation of TGF-beta signaling is frequently observed in various cancers.
- Smad6 and Smad7 are key inhibitory genes within the TGF-beta pathway.
Purpose of the Study:
- To investigate the potential role of Smad6 and Smad7 gene mutations in human ovarian cancers.
- To identify any genetic alterations in Smad6 and Smad7 within ovarian tumor samples and cell lines.
Main Methods:
- Polymerase Chain Reaction-Single Strand Conformation Polymorphism (PCR-SSCP) analysis was employed.
- The study analyzed DNA from 30 human ovarian cancer tissues and 4 ovarian cancer cell lines.
- Sequencing was performed to characterize identified genetic variations.
Main Results:
- A polymorphism in intron 2 of the Smad6 gene was detected in 35.3% of cases.
- A polymorphism at codon 208 of the Smad7 gene was found in 23.5% of cases.
- These identified polymorphisms did not result in any amino acid substitutions.
Conclusions:
- The observed polymorphisms in Smad6 and Smad7 genes are unlikely to be causative mutations in human ovarian cancers.
- Further research may be needed to explore other genetic or epigenetic factors in ovarian tumorigenesis.
- The findings suggest Smad6 and Smad7 mutations are not a significant driver in this cohort of ovarian cancers.
